Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study

BACKGROUND: Apatinib is an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Some clinical trials have demonstrated that apatinib is efficacious against advanced nonsquamous NSCLC. OBJECTIVE: This study aimed to probe efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qian, Zhang, Ning-Ling, Ma, Dai-Yuan, Tan, Bang-Xian, Hu, Xin, Fang, Xiang-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616323/
https://www.ncbi.nlm.nih.gov/pubmed/31261514
http://dx.doi.org/10.1097/MD.0000000000016065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616323/
https://www.ncbi.nlm.nih.gov/pubmed/31261514
http://dx.doi.org/10.1097/MD.0000000000016065

Ejemplares similares